Database analysis of patients with Autosomal Dominant Polycystic Kidney Disease
Official title: Analysis of Patients With Autosomal Dominant Polycystic Kidney
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06759142 · Data updated 2026-11-12
This study is trying to gather and track health information from people with Autosomal Dominant Polycystic Kidney Disease to see how different treatments affect their kidney function and cyst growth over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna) |
| Status | Recruiting |
| Started | February 20, 2021 |
| Main results expected | June 1, 2025 |
| Study ends | June 1, 2025 |
| Registry record updated | January 6, 2025 |
| Trial ID | NCT06759142 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with ADPKD, particularly those who have undergone specific therapies.
✕Probably not a fit
Patients without a diagnosis of ADPKD or those who do not meet the inclusion criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to create a comprehensive database of clinical and genetic data for patients diagnosed with Autosomal Dominant Polycystic Kidney Disease (ADPKD), particularly those who have received treatments like Tolvaptan or Octreotide. It will involve collecting detailed personal and family histories, and monitoring clinical outcomes over time. The research will focus on understanding the relationship between genetic variants and disease progression, specifically tracking the impact of therapies on renal function and cyst growth. Data will be continuously updated during outpatient visits to ensure accurate monitoring of disease progression.
Why it matters
Potential benefit: If successful, this study could enhance understanding of ADPKD and improve treatment strategies for patients.
How similar studies have gone: While similar studies have been conducted, this specific approach focusing on genotype-phenotype correlation in ADPKD patients receiving targeted therapies is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age-matched subjects with a diagnosis of ADPKD defined on the basis of the Unified Criteria of Pei. Diagnosis in subjects with a positive family history is based on age-differentiated ultrasound criteria. The presence of a "total of 3 or more cysts" in subjects aged 18-39 years and "2 or more cysts in each kidney" in at-risk subjects aged 40-59 years are sufficient to make the diagnosis of ADPKD.In the absence of family history, the presence of more than 10 cysts per kidney on ultrasound is typically considered diagnostic. Where the picture appears unclear, and particularly where the diagnosis has a major fallout (related to family planning, renal donation, initiation of specific drug treatment), genetic confirmation is strongly recommended. * Obtaining Informed Written Consent. Exclusion Criteria: * None.
Where it's running
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy Recruiting
Study contacts
- Principal investigator: Gaetano La Manna, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Gaetano La Manna, MD
- Email: gaetano.lamanna@unibo.it
- Phone: +390512144577
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Mapping sensory pain patterns in ADPKD
This project will test whether detailed sensory testing and short questionnaires can identify characteristic pain patterns in people aged 12 and older with ADPKD compared with matched healthy volunteers.
-
Using a medication to slow kidney growth in patients with a genetic kidney disease
This study is testing if a new medication can help slow down kidney growth in overweight or obese adults with a genetic kidney disease called ADPKD.
-
Evaluating the role of genetics in kidney disease progression
This study is trying to see how genetics affects the worsening of kidney diseases like acute kidney injury and chronic kidney disease in people, especially those with high blood pressure.
-
Using RNA sequencing to diagnose rare genetic diseases
This study is testing if a new RNA sequencing method can help find the genetic causes of rare diseases in people who haven't been diagnosed after other tests.
-
Using a GnRH Agonist to Treat Severe Polycystic Liver Disease in Women
This study is testing if a medication called leuprorelin can help reduce liver size in women with severe polycystic liver disease who are still experiencing growth despite other treatments.
-
Hydrochlorothiazide added to tolvaptan to protect kidneys and improve quality of life in ADPKD
This trial tests whether adding low-dose hydrochlorothiazide to adults with ADPKD who are already taking tolaptan slows kidney decline and reduces side effects like excessive urination.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.